Cargando…

Complex renal cysts associated with crizotinib treatment

An apparent causal association between crizotinib treatment and renal cyst development emerged during clinical trials in anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Serious adverse event (SAE) reports of renal cysts from a safety database of 1375 patients from four...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnell, Patrick, Bartlett, Cynthia H, Solomon, Benjamin J, Tassell, Vanessa, Shaw, Alice T, de Pas, Tommaso, Lee, Soo-Hyun, Lee, Geon Kook, Tanaka, Kaoru, Tan, Weiwei, Tang, Yiyun, Wilner, Keith D, Safferman, Allan, Han, Ji-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472211/ https://www.ncbi.nlm.nih.gov/pubmed/25756473 http://dx.doi.org/10.1002/cam4.437

Ejemplares similares

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)
por: Ou, Sai‐Hong Ignatius, et al.
Publicado: (2016)

Crizotinib targets in glioblastoma stem cells
por: Junca, Audelaure, et al.
Publicado: (2017)

Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
por: Cameron, Laird B, et al.
Publicado: (2017)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
por: Nishio, Makoto, et al.
Publicado: (2018)

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
por: Blackhall, Fiona, et al.
Publicado: (2017)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe
por: Huang, Kui, et al.
Publicado: (2020)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study
por: Waterhouse, David, et al.
Publicado: (2021)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
por: Shen, Lan, et al.
Publicado: (2020)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
por: Shaw, A T, et al.
Publicado: (2019)

Association of anticoagulant use with clinical outcomes from crizotinib in ALK ‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001
por: Ng, Terry L., et al.
Publicado: (2022)

Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
por: Selaru, P, et al.
Publicado: (2016)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)

Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case
por: Kaseda, Kaoru, et al.
Publicado: (2015)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Diagnostic potential of tumor DNA from ovarian cyst fluid
por: Wang, Yuxuan, et al.
Publicado: (2016)

Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)

Crizotinib: Pneumonitis: case report
Publicado: (2021)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
por: Yang, Guangjian, et al.
Publicado: (2019)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Trichilemmal Carcinoma from Proliferating Trichilemmal Cyst on the Posterior Neck
por: Kim, Ui Geon, et al.
Publicado: (2017)

Crizotinib-induced Rectal Perforation with Abscess
por: Yanagisawa, Asako, et al.
Publicado: (2017)

Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung
por: Batra, Ullas, et al.
Publicado: (2018)

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
por: Wu, Yi-Long, et al.
Publicado: (2022)

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis
por: Chen, Weiwei, et al.
Publicado: (2021)

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
por: Li, Jerry, et al.
Publicado: (2021)

Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer
por: Wang, Guosen, et al.
Publicado: (2020)

Shikonin inhibits proliferation of melanoma cells by MAPK pathway-mediated induction of apoptosis
por: Lee, Jae Han, et al.
Publicado: (2021)

Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report
por: Amano, Yosuke, et al.
Publicado: (2022)

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
por: Aparicio, Thomas, et al.
Publicado: (2021)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

The circadian rhythm and core gene Period2 regulate the chemotherapy effect and multidrug resistance of ovarian cancer through the PI3K signaling pathway
por: Wang, Zhaoxia, et al.
Publicado: (2020)

Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
por: Jalil, Ala' A Abdel, et al.
Publicado: (2014)

Crizotinib-Induced Abnormal Signal Processing in the Retina
por: Ishii, Toshiyuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kqmgj8rsbinu3b05hvvu3skgai